UK LEADER IN BREAKTHROUGH MEDICINES
Improving quality of life for patients
WHAT WE DO
MANUFACTURE | SUPPLY
An EU-GMP licensed 100,000 sq ft UK facility, producing active pharmaceutical ingredients
CLINICAL TRIALS
An MHRA-approved clinical trial in chronic pain, with further studies progressing in endometriosis and other unmet needs
R&D PIPELINE
In-house IP generation and a development pipeline of prescription medicines, including a partnered programme in autism spectrum disorder
OUR MISSION
Celadon’s mission is to improve quality of life for patients most in need by developing
breakthrough medicines
Celadon was founded in 2018 to develop prescription medicines for patients who aren’t well served by what’s currently available.
Everything at Celadon starts with improving patients’ quality of life. The primary focus is on two of the largest underserved patient populations in the market: chronic pain and endometriosis.
Chronic pain affects an estimated 8 million adults in the UK, 50 million in the US and 100 million across Europe, where the limitations of opioid-based treatment are now well documented and the search for non-opioid alternatives is a stated public-health priority.
Endometriosis affects around 1 in 10 women of reproductive age, approximately 1.5 million in the UK and 190 million worldwide, and costs the UK economy an estimated £8.2 billion a year in healthcare, lost work and care. As the second most common gynaecological condition in the UK, it is served largely by analgesics, hormonal therapies and surgery, with effective non-hormonal options conspicuously absent.
Celadon operates as a vertically integrated pharmaceutical company, with the manufacturing capability, regulatory authorisations and clinical programme to deliver on its patient-first mission.
Its EU-GMP licensed 100,000 sq ft facility combines cultivation, extraction and Delta-9 THC production on a single site, manufacturing active pharmaceutical ingredients under MHRA and Home Office Controlled Drug authorisation covering Schedules 1 and 2.
The company’s MHRA-approved chronic pain trial, conducted through its subsidiary LVL Health, is designed to generate the data set needed to support NHS reimbursement, alongside a programme in endometriosis.
In-house R&D continues to generate novel intellectual property, and a partnership with biopharma Kingdom Therapeutics is developing a licensed prescription medicine for autism spectrum disorder.
OUR JOURNEY
In a market with significant regulatory and capital barriers to entry, Celadon is building the UK’s leading pharmaceutical cannabinoid company.
Celadon founded after medical cannabis legalisation in UK.
Celadon applies to UK regulators and MHRA, helping create the UK’s regulatory framework for cultivation and production.
Celadon successfully granted licence by UK regulators for legal cultivation of test batches of high THC cannabis.
Phase 1 of construction is completed at Celadon’s 100,000 sq ft UK facility, and first harvest is completed.
Acquisition of majority shareholding in LVL Health , which has the only MHRA conditionally approved chronic pain trial using cannabis based medicines.
Acquisition of minority stake in Kingdom Therapeutics, a UK leading biopharma developing a licensed cannabinoid treatment for autism spectrum disorder.
Phase 2 construction begins, which will take Celadon’s cultivation capacity to around 3 tonnes once complete.
Celadon completes in 7th harvest in the summer of 2022, to support its MHRA application for EU-GMP for its high-THC cannabinoid API.
LVL’s chronic pain trial enrols its first patients, with early results very promising for the reduction of pain (and opioid usage) and increasing sleep.
Celadon receives its GMP registration from the MHRA, following a successful site inspection.
First international shipment is approved to a U.S. DEA-licensed customer, establishing compliant export into the U.S. market.
Grant of the General Pharmaceutical Council (GPhC) licence supports regulated pharmaceutical supply and contributes to shorter patient waiting times in the UK.
Celadon granted updated licence by UK regulators allowing the commercial sale of its pharmaceutical product.
Semi-Synthetic Delta-9 THC, extending the company's pharmaceutical manufacturing capability into synthesised API alongside its plant-derived route.
Launch of Celadon's propretary Delta-9 THC vaginal pessary, with an obersational study initiated in patients with endometriosis-associated pain.
BUILDING ON STRONG FOUNDATIONS
Discover more about our company, explore our achievements, and read the latest updates
WORKING WITH REGULATORS
Celadon holds MHRA EU-GMP certification for the manufacture of active pharmaceutical ingredients, a Home Office Controlled Drug Licence covering Schedules 1 and 2, and a General Pharmaceutical Council registration supporting regulated pharmaceutical supply.
Celadon's UK facility produces active pharmaceutical ingredients under EU-GMP for regulated API supply into the prescription medicines market. The capability is held by a small number of UK companies, and underpins the company's pipeline of prescription medicines.
CANPAIN, Celadon's MHRA-approved chronic pain clinical trial conducted through subsidiary LVL Health, is a regulator-sanctioned study designed to generate the data required to support NHS reimbursement. A separate observational study in endometriosis runs in parallel.
